Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2026 19:00 ET | Source: TermPlus

New Diversified Monthly Income Strategy for SMSF Trustees June 2026 Update - TermPlus Launches High-Yield Fixed-Term Accounts

Sydney, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Australian superannuation regulations require self-managed super funds to maintain a documented investment strategy that covers asset allocation,...
June 17, 2026 08:47 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
June 17, 2026 08:00 ET | Source: Elicio Therapeutics Inc.

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based...
June 16, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

New York, USA, June 16, 2026 (GLOBE NEWSWIRE) -- Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight The glioblastoma clinical trial...
June 16, 2026 08:33 ET | Source: Entera Bio Ltd.

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected...
June 16, 2026 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
June 16, 2026 07:00 ET | Source: NovaBridge Biosciences

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE...
June 16, 2026 05:44 ET | Source: VRURC

VRURC Launches T009 Qi2 Foldable 3-in-1 Magnetic Wireless Charger, Now Available for Pre-Order at 62% Off Ahead of June 20 Release

VRURC T009 3-in-1 Qi2 mag charger for Apple. 25W fast charge, dual cooling, retractable cable. Pre-order 62% off til June 20, 2026. 2y warranty.
June 15, 2026 13:36 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Corporate Update

Orocidin's QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone lossPhase IIa clinical trial in patients planned H1 2027 at the University of...
June 15, 2026 08:45 ET | Source: Entera Bio Ltd.

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613...